Advertisement
SEATTLE (AP) — ZymoGenetics Inc. said Thursday that its drug candidate Atacicept did not meet goals that would have automatically advanced it to late-stage clinical testing as a treatment for rheumatoid arthritis. ZymoGenetics said its partner Merck Serono has not made a decision about whether the late-stage trials will be conducted. Atacicept is also being tested as a treatment for lupus and multiple sclerosis.
Advertisement
Advertisement